zur Startseite


Veranstalter, Ort

Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).

Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V.
read more ›

How I treat rituximab refractory patients with WM.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA.
read more ›


Presentations on WM at this year‘s ASH 2013 in New Orleans

from our consortium on:

  • Elevated Von Willebrand Factor Antigen Serum Levels and their association with poor prognosis In patients with symptomatic Waldenstrom’s Macroglobulinemia  (Efstathios Kastritis et al., Athens, Greece)
  • Disease unrelated mortality accounting for differences in survival in patients >75 Years with symptomatic Waldenström’s Macroglobulinemia  (Efstathios Kastritis et al., Athens, Greece)
  • Newest update of the WM2 trial on the efficacy of Bortezomib in patients with advanced Waldenström Macroglobulinemia  (V. Leblond et al., Paris, France)
‹ back